Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials.

Patrick M O'NeilVanita R ArodaArne AstrupRobert KushnerDavid C W LauThomas A WaddenJason BrettAna-Paula CancinoJohn P H Wildingnull null

Published in: Diabetes, obesity & metabolism (2017)

Results of this exploratory pooled analysis provide no cause for concern regarding the neuropsychiatric safety of treatment with liraglutide 3.0 mg in patients similar to those included in the examined trials. Although there was a small numerical imbalance in suicidal ideation with liraglutide through adverse event reporting, no between-treatment imbalances in suicidal ideation/behaviour or depression were noted through prospective questionnaire assessments.

Keyphrases

end stage renal disease
ejection fraction
physical activity
chronic kidney disease
depressive symptoms
body mass index
open label
randomized controlled trial
weight loss
peritoneal dialysis
adverse drug
patient reported
sleep quality
phase ii
weight gain
phase iii